Latest by Myles Helfand
Unmet subsistence needs and clinical outcomes; finding HIV treatment success alongside quality-of-life issues; the potential value of facility-level HIV care continuum data; stimulant use and viral suppression.
The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.
The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
Real-world treatment efficacy high, but falls short of trials; parental communication and PrEP awareness among adolescent MSM; immunotherapy feasible in people with HIV and cancer; AIDS-defining illness increases mortality risk in lung cancer patients.
Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?
A cellphone attachment that detects HIV RNA; HIV-2 does indeed often progress to AIDS; CD4 count declines and incident hepatitis C coinfection; the global demographics of non-Hodgkin lymphoma.
High HIV prevalence among black MSM on PrEP; substance use reduction lessens depressive symptoms; correlations between pain symptoms and age; the impact of seroconversion and antiretroviral therapy on risk behaviors.
The case for a new measurement of HIV treatment success; PrEP and HIV incidence in Australia; benefits of moderate exercise among older people with HIV; CD4 recovery rates after long-term viral suppression.
PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.
Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.